Company Information

  

Address: 110 ALLEN ROAD
SECOND FLOOR 
City: BASKING RIDGE 
State: NJ 
Zip Code: 07920 
Telephone: 908-842-0100 

Description of Business

Primary SIC Code: 8090
(As filed with the SEC)  

Caladrius Biosciences, Inc. ("we," "us," "our," "Caladrius" or the "Company"), is a company developing cellular therapeutics to treat certain diseases. We leverage our internal specialized cell therapy clinical development expertise to select and develop early-stage cell therapy candidates with the intention of partnering these candidates post proof-of-concept in humans. Our current lead product candidate, CLBS03, is an autologous ex vivo polyclonal T regulatory cell ("Treg") clinical phase 2 therapy targeting adolescents with recent-onset type 1 diabetes mellitus ("T1D"). Our subsidiary, PCT, LLC, a Caladrius CompanyTM ("PCT"), is a leading provider of development and manufacturing services to the cell and cell-based gene therapy industry. PCT has significant cell therapy-specific experience and expertise, an expansive list of noteworthy clients and significant revenue growth over the past three years. Notably, PCT and Hitachi Chemical Co. America, Ltd.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
06/2017-2.66NAN/E
03/2017-4.02NAN/E
12/2016-4.99NAN/E
09/2016-10.75NAN/E
06/2016-112.60NAN/E
03/2016-137.00NAN/E

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2016 Leverage 2016
Net Inc/Comm Equity-0.08Total Liab/Total Assets0.53
Net Inc/Total Assets-0.63Total Liab/Inv Cap0.97
Net Inc/Inv Cap-1.15Total Liab/Comm Equity0.07
Pretax Inc/Net Sales-0.94Interest Coverage Ratio-16.86
Net Inc/Net Sales-0.93Curr Debt/Equity0.81
Cash Flow/Net Sales-0.67LTD/Equity0.58
SG&A/NetSales0.58Total Debt/Equity1.39
Asset Utilization   Liquidity  
Net Receivables Turnover12.93Quick Ratio1.26
Inventory TurnoverNACurrent Ratio1.26
Inventory Day SalesNANet Rec/Curr Assets0.12
Net Sales/Work Cap6.85Inv/Curr AssetsNA
Net Sales/PP&E2.06  

Income Statement (Millions)

  3/31/2017 12/31/2016 9/30/2016 3/31/2016
Total Revenues(Net Sales) 7.92 10.18 25.11 7.49
Cost of Goods Sold 8.04 9.25 21.89 6.23
Selling & Admin Exps 5.95 4.27 8.36 6.46
Operating Income -9.53 -5.92 -7.14 -11.07
Interest Exp 0.17 0.19 0.44 0.93
Pretax Income -9.74 -6.10 -7.57 -11.99
Other Income -0.04 0.00 0.00 0.01
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -9.36 -5.96 -6.77 -11.98

Balance Sheet (Millions)

Assets 3/31/2017 12/31/2016 9/30/2016 3/31/2016
Cash & Short Term Investments 12.00 14.71 18.61 25.43
Receivables - Total 3.17 2.89 4.27 2.61
Inventories - Total NA NA NA NA
Total Current Assets 21.93 24.65 29.96 35.62
Net Property, Plant & Equipment 16.76 17.15 17.12 16.92
Total Assets 48.53 51.83 57.28 63.18
Liabilities        
Accounts Payable 13.64 10.43 9.62 10.31
Debt in Current Liabilities 4.21 3.97 3.07 2.52
Total Current Liabilities 23.21 19.50 18.55 18.46
Long-Term Debt 1.92 2.82 3.56 7.94
Total Liabilities 29.92 27.55 27.13 30.12
Stockholder's Equity        
Minority Interest -1.18 -0.82 -0.76 -0.48
Preferred Stock 0.00 0.00 0.00 0.00
Common Stock 0.01 0.01 0.01 0.06
Retained Earnings -414.15 -404.79 -398.83 -384.11
Treasury Stock -0.71 -0.71 -0.71 -0.71
Total Stockholders' Equity -0.79 4.88 10.75 13.66
Total Liabilities and Stockholders' Equity 29.13 32.43 37.88 43.78

Cash Flow Summary (Millions)

Categories 3/31/2017 12/31/2016 9/30/2016 3/31/2016
Net Cash Provided by Operating Activities -10.09 -3.38 -5.72 -8.03
Net Cash Provided by Investing Activities -0.17 -0.53 -0.61 -1.04
Net Cash Provided by Financing Activities 7.55 0.01 7.24 14.18

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/201214.33-53.77--
12/201314.67-38.98--
12/201417.94-54.87--
12/201522.49-80.89--
12/201635.28-32.66-4.99
Growth Rates25.27----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/17286096.47




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.